Hologic, Inc. (HOLX)

Hologic, Inc. (HOLX - Analyst Report) reported fourth quarter earnings of 28 cents per share, above the Zacks Consensus Estimate of 26 cents, but a couple of cents below the year-ago earnings. For fiscal 2009, the company earned $1.17 per share, a cent below the year-ago earnings.

Revenues declined 8.9% in the reported quarter and 2% in fiscal 2009. We remain concerned about the decline, which is largely attributable to the stringent economic and capital spending environment.

Furthermore, Hologic's strategy to grow by acquisitions has inherent risks. Strong competition confronting the company's products also concerns us. Consequently, we downgrade the stock to Underperform with a price target of $14.

Hologic, Inc. (HOLX) : FULL ANALYST REPORT

Email	Print	Share	RSS	Rate Pos	Rate Neg	Comment

Loading Stories...

Related Content

RELATED ARTICLES BEAR OF THE DAY ARCHIVE

Zacks Blog: Hologic Surpasses Zacks Estimate
(HOLX)	02/02/10
Zacks Blog: Hologic Upgraded Pre-Earnings
(HOLX)	02/01/10
Zacks Equity Research: Report For HOLX
N/A	01/27/10
Zacks Blog: Zacks Bull and Bear of the Day Highlights: Sealed Air Corporation, Hologic, Inc., Genzyme Corp., Shire plc and Protalix BioTherapeutics Inc.
(SEE, HOLX, GENZ, SHPGY, PLX)	11/17/09
Zacks Blog: Zacks #5 Rank Additions for Thursday
(AMCN, ATAI, CFFN, CRH, ESGR, CGV, HOLX, INXI, LIHR, OSTE, PIKE, QGEN, SMHG, T)	11/12/09

 Posting Comment...

There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]

Comments (Limit 1000 Characters - Used: 0)

Please provide your comments here... Display Name: Email Address:  

 Loading Comments...

Be the first to comment on this article!